Contributors
Ken Hallenbeck
Ken Hallenbeck earned a Ph.D. in pharmaceutical sciences from the University of California, San Francisco, and now is an early drug-discovery researcher. He serves on the board of directors of ReImagine Science and is the life sciences lead at TerraPrime.
Articles by Ken Hallenbeck
Journal News
Sibling study reveals mechanism for genetic disease
Feb. 13, 2024
Using proteomics experiments, researchers found that old proteins pile up in the mitochondria of people with a form of adult-onset muscular dystrophy.
Journal News
A downside to liposome drug delivery?
March 7, 2023
When researchers injected mice with liposomes, they found that white blood cells showed signs of stress, leading to decreased ability to create immune cell types.
Essay
What is better for your career than a publication? A preprint.
Sept. 22, 2022
鈥淒epositing a paper outside of an academic journal allows an author to start promoting the work immediately,鈥� Ken Hallenbeck writes.
Essay
It is finally time for post-publication review
Feb. 3, 2022
The internet has rewritten the rules of print publishing over the last three decades. Why hasn鈥檛 it had the same impact on the discussion that follows?
Journal News
What鈥檚 growing in your mouth might change with your health
Dec. 21, 2021
A recent paper in the journal Molecular & Cellular Proteomics takes a tech-enabled deep dive into dental plaques.
Reimagining
Challenging science stereotypes with a video game
July 7, 2021
Imagine a digital game set in a lab that creates a research experience accessible to all and populated by all.
Essay
The evolution of proteins from mysteries to medicines
Feb. 27, 2021
An essay in observance of National Protein Day.
Life in the Lab
Time for a new model of data disclosure?
July 15, 2020
Ken Hallenbeck asserts that a flood of scientific papers related to the pandemic provides an opportunity to review core assumptions of the modern publication model.